{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:26:48Z","timestamp":1792218408350,"version":"4.4.0"},"reference-count":135,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1076282"],"award-info":[{"award-number":["2020R1F1A1076282"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE.<\/jats:p>","DOI":"10.3390\/ijms21218165","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T21:39:56Z","timestamp":1604180396000},"page":"8165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":313,"title":["Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"21","author":[{"given":"Young","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung Won","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Young Jang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jae Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, Soonchunhyang University College of Medicine, Seoul 04401, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000343867","article-title":"How to define transarterial chemoembolization failure or refractoriness: A European perspective","volume":"3","author":"Raoul","year":"2014","journal-title":"Liver Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrclinonc.2014.122","article-title":"Treatment of intermediate-stage hepatocellular carcinoma","volume":"11","author":"Forner","year":"2014","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00270-014-0907-0","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: Clinical-radiological outcomes and safety profile","volume":"38","author":"Spreafico","year":"2015","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jvir.2014.12.020","article-title":"Safety and efficacy of 70\u2013150 mum and 100\u2013300 mum drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"26","author":"Deipolyi","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00270-017-1839-2","article-title":"Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study","volume":"41","author":"Richter","year":"2018","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis","volume":"48","author":"Facciorusso","year":"2016","journal-title":"Dig. Liver Dis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","article-title":"Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: Comparison between drug-eluting beads and lipiodol emulsion","volume":"27","author":"Monier","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0284185116648501","article-title":"Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: Comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study","volume":"58","author":"Lee","year":"2017","journal-title":"Acta Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000507262","article-title":"Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma","volume":"98","author":"Shimose","year":"2020","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00270-012-0476-z","article-title":"Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: Measurement of balloon-occluded arterial stump pressure","volume":"36","author":"Irie","year":"2013","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4254\/wjh.v10.i7.485","article-title":"Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"10","author":"Hatanaka","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/hepr.12403","article-title":"Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma","volume":"45","author":"Arai","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/hepr.12564","article-title":"Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE","volume":"46","author":"Irie","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1111\/hepr.12527","article-title":"Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results","volume":"46","author":"Ogawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","article-title":"Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma","volume":"59","author":"Cucchetti","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Eng. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ajg.2014.152","article-title":"Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller","volume":"109","author":"Kim","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1394143","article-title":"Systemic therapy for hepatocellular carcinoma: The issue of treatment stage migration and registration of progression using the BCLC-refined RECIST","volume":"34","author":"Reig","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ejrad.2011.03.046","article-title":"Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study","volume":"81","author":"Bargellini","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.24246","article-title":"Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas","volume":"53","author":"Golfieri","year":"2011","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3904\/kjim.2018.058","article-title":"Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization","volume":"34","author":"Baek","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1600-6143.2009.02576.x","article-title":"Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation","volume":"9","author":"Sze","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2214\/AJR.07.2972","article-title":"Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation","volume":"190","author":"Alba","year":"2008","journal-title":"AJR Am. J. Roentgenol"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s11605-007-0211-2","article-title":"A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation","volume":"11","author":"Aloia","year":"2007","journal-title":"J. Gastrointest. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/lt.21033","article-title":"Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma","volume":"13","author":"Millonig","year":"2007","journal-title":"Liver Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/lt.20837","article-title":"Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma","volume":"12","author":"Otto","year":"2006","journal-title":"Liver Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jhep.2013.04.006","article-title":"How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?","volume":"59","author":"Otto","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Eng. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2036.2006.03029.x","article-title":"Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong","volume":"24","author":"Cheung","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1746.2007.05112.x","article-title":"Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area","volume":"23","author":"Park","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1245\/s10434-010-0940-4","article-title":"Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus","volume":"17","author":"Shi","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","article-title":"Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma","volume":"4","author":"Omata","year":"2010","journal-title":"Hepatol. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, and European Organisation for Research and Treatment of Cancer (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 56, 908\u2013943.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int."},{"key":"ref_55","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s12032-011-0145-0","article-title":"Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: Using a new classification","volume":"29","author":"Niu","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: A prospective comparative study","volume":"18","author":"Luo","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Xue, T.C., Xie, X.Y., Zhang, L., Yin, X., Zhang, B.H., and Ren, Z.G. (2013). Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-60"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","article-title":"The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2014.11.014","article-title":"Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process","volume":"62","author":"Adhoute","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2013.08.022","article-title":"The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE","volume":"60","author":"Hucke","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1159\/000368007","article-title":"The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series","volume":"32","author":"Terzi","year":"2014","journal-title":"Dig. Dis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/hep.26760","article-title":"Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"59","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000440625","article-title":"Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma","volume":"89","author":"Arizumi","year":"2015","journal-title":"Oncology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jvir.2016.06.012","article-title":"Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma","volume":"28","author":"Kloeckner","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep.24670","article-title":"Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques","volume":"54","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000368142","article-title":"Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3350\/cmh.2018.0065","article-title":"A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3350\/cmh.2019.0021n","article-title":"Switching to systemic therapy after locoregional treatment failure: Definition and best timing","volume":"26","author":"Ogasawara","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s10620-015-4018-9","article-title":"The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma","volume":"61","author":"Kajihara","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4143\/crt.2019.533","article-title":"Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure\/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma","volume":"52","author":"Xue","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13046-019-1246-4","article-title":"SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway","volume":"38","author":"Zhao","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","article-title":"Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases","volume":"27","author":"Jung","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","article-title":"Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"87","author":"Ogasawara","year":"2014","journal-title":"Oncology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000367743","article-title":"Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma","volume":"4","author":"Arizumi","year":"2015","journal-title":"Liver Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1148\/radiol.11110637","article-title":"Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: A prospective randomized trial","volume":"262","author":"Peng","year":"2012","journal-title":"Radiology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jvir.2017.05.015","article-title":"Combined Therapy of Transcatheter Arterial Chemoembolization and Radiofrequency Ablation versus Surgical Resection for Single 2\u20133 cm Hepatocellular Carcinoma: A Propensity-Score Matching Analysis","volume":"28","author":"Lee","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clinre.2015.07.008","article-title":"Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis","volume":"40","author":"Chen","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.3748\/wjg.v19.i24.3872","article-title":"Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma","volume":"19","author":"Ni","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2008.11.002","article-title":"Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"92","author":"Meng","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1440-1746.2001.02496.x","article-title":"Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement","volume":"16","author":"Tazawa","year":"2001","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1386-6346(03)00162-1","article-title":"Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients","volume":"27","author":"Seong","year":"2003","journal-title":"Hepatol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","article-title":"Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: Long-term patient outcomes","volume":"82","author":"Yoon","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000367766","article-title":"Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials","volume":"5","author":"Park","year":"2016","journal-title":"Liver Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.07.1730","article-title":"Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus","volume":"78","author":"Koo","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Randomized Clinical Trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): A randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000481243","article-title":"Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)","volume":"93","author":"Kudo","year":"2017","journal-title":"Oncology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000501501","article-title":"Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","article-title":"Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials","volume":"92","author":"Kudo","year":"2017","journal-title":"Oncology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000485471","article-title":"Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit\/Risk Assessment","volume":"7","author":"Piscaglia","year":"2018","journal-title":"Liver Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2014.07.002","article-title":"How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","volume":"61","author":"Hucke","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cgh.2014.11.037","article-title":"Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification","volume":"13","author":"Pinato","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/liv.12878","article-title":"Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score","volume":"36","author":"Park","year":"2016","journal-title":"Liver Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/liv.12865","article-title":"Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: Development of a prediction model","volume":"36","author":"Kim","year":"2016","journal-title":"Liver Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jhep.2015.02.034","article-title":"Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"63","author":"Xu","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/liv.13029","article-title":"Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma","volume":"36","author":"Cappelli","year":"2016","journal-title":"Liver Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/liv.14194","article-title":"A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma","volume":"39","author":"Lee","year":"2019","journal-title":"Liver Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.31022","article-title":"Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach","volume":"72","author":"Han","year":"2020","journal-title":"Hepatology"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Fan, W., Zhang, Y., Wang, Y., Yao, X., Yang, J., and Li, J. (2015). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119312"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.3892\/ol.2016.4359","article-title":"Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization","volume":"11","author":"Zhou","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/CMAR.S190545","article-title":"The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy","volume":"11","author":"He","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Chon, Y.E., Park, H., Hyun, H.K., Ha, Y., Kim, M.N., Kim, B.K., Lee, J.H., Kim, S.U., Kim, D.Y., and Ahn, S.H. (2019). Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel), 11.","DOI":"10.3390\/cancers11040509"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.it.2015.11.008","article-title":"Neutrophils in the Tumor Microenvironment","volume":"37","author":"Powell","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/bjc.2013.785","article-title":"The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer","volume":"110","author":"Stotz","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e8512","DOI":"10.1097\/MD.0000000000008512","article-title":"Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltim.)"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e22999","DOI":"10.1002\/jcla.22999","article-title":"Prognostic significance of the CRP\/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA","volume":"33","author":"Shen","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Xiao, W.K., Chen, D., Li, S.Q., Fu, S.J., Peng, B.G., and Liang, L.J. (2014). Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-117"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3322\/caac.21552","article-title":"Artificial intelligence in cancer imaging: Clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3109\/0284186X.2015.1061214","article-title":"External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma","volume":"54","author":"Leijenaar","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_125","first-page":"CD013186","article-title":"Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults","volume":"12","author":"Takwoingi","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: Extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images Are More than Pictures, They Are Data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00261-019-02299-3","article-title":"State-of-the-art in radiomics of hepatocellular carcinoma: A review of basic principles, applications, and limitations","volume":"45","author":"Assuncao","year":"2020","journal-title":"Abdom. Radiol. (NY)"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Lewis, S., Hectors, S., and Taouli, B. (2020). Radiomics of hepatocellular carcinoma. Abdom. Radiol. (NY), Online ahead of print.","DOI":"10.1007\/s00261-019-02378-5"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2214\/AJR.18.19507","article-title":"Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics","volume":"211","author":"Kim","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3389\/fonc.2020.01196","article-title":"Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization","volume":"10","author":"Meng","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jmri.27143","article-title":"Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI","volume":"52","author":"Sun","year":"2020","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.18632\/oncotarget.23423","article-title":"Signature of survival: A (18)F-FDG PET based whole-liver radiomic analysis predicts survival after (90)Y-TARE for hepatocellular carcinoma","volume":"9","author":"Jreige","year":"2018","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1007\/s00330-020-06931-5","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE","volume":"30","author":"Schobert","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.jhepr.2020.100100","article-title":"Evaluation of liver tumour response by imaging","volume":"2","author":"Gregory","year":"2020","journal-title":"JHEP Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:46Z","timestamp":1760178466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":135,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21218165"],"URL":"https:\/\/doi.org\/10.3390\/ijms21218165","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]}}}